Data / Drug companies / Gilead Sciences, Inc.
Gilead Sciences, Inc.: 50 products in the FDA NDC directory, labeler code 61958
Gilead Sciences, Inc. (labeler code 61958) lists 50 products in the FDA National Drug Code Directory, covering 19 finished drugs by generic name. By type: 50 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 31, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 61958
- Products in commercial distribution
- 50
- Packages
- 65
- Finished drugs by generic name
- 19
- Prescription products
- 50
- Over the counter products
- 0
- Flagged as original packager
- 42 of 42 products that carry the flag
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 5
- Earliest marketing start
- October 26, 2001
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 49 | 98% |
| Biologics (BLA) | 1 | 2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 50 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Tenofovir disoproxil fumarate | 5 | 16 |
| Lenacapavir sodium | 5 | 1 |
| Emtricitabine and tenofovir disoproxil fumarate | 4 | 28 |
| Sofosbuvir | 4 | 1 |
| Ledipasvir and sofosbuvir | 4 | 2 |
| Velpatasvir and sofosbuvir | 4 | 2 |
| Ambrisentan | 2 | 13 |
| Emtricitabine and tenofovir alafenamide | 2 | 1 |
| Emtricitabine | 2 | 3 |
| Idelalisib | 2 | 1 |
| Cobicistat | 1 | 1 |
| Seladelpar lysine | 1 | 1 |
| Sofosbuvir, velpatasvir, and voxilaprevir | 1 | 1 |
| Bictegravir/lenacapavir | 1 | 1 |
| Tenofovir alafenamide | 1 | 1 |
| Bictegravir/lenacapavir, lenacapavir sodium | 1 | 1 |
| Aztreonam | 1 | 5 |
| Bulevirtide | 1 | 1 |
| Remdesivir | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 21 | 42% |
| Tablet | 8 | 16% |
| Pellet | 6 | 12% |
| Kit | 5 | 10% |
| Tablet, coated | 4 | 8% |
| Capsule | 2 | 4% |
| Injection, powder, lyophilized, for solution | 2 | 4% |
| Solution | 1 | 2% |
| Powder | 1 | 2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 21 |
| Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 19 |
| Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor | 13 |
| Hepatitis C Virus NS5A Inhibitor | 9 |
| Cytochrome P450 3A Inhibitor | 3 |
| Human Immunodeficiency Virus 1 Capsid Inhibitor | 3 |
| Endothelin Receptor Antagonist | 2 |
| Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 2 |
| Kinase Inhibitor | 2 |
| Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor | 2 |
| Hepatitis C Virus NS3/4A Protease Inhibitor | 1 |
| SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Bixlenvo Sunlenca Starter Pack | 61958-3701 | Kit | New drug applications (NDA) | October 31, 2026 |
| Bixlenvo | 61958-3601 | Tablet, film coated | New drug applications (NDA) | August 27, 2026 |
| Hepcludex | 61958-3104 | Injection, powder, lyophilized, for solution | Biologics (BLA) | May 22, 2026 |
| Yeztugo | 61958-3402 | Kit | New drug applications (NDA) | June 18, 2025 |
| Yeztugo | 61958-3401 | Tablet, film coated | New drug applications (NDA) | June 18, 2025 |
| Sunlenca | 61958-3005 | Kit | New drug applications (NDA) | March 18, 2025 |
| Biktarvy | 61958-2506 | Tablet | New drug applications (NDA) | October 8, 2024 |
| Livdelzi | 61958-3301 | Capsule | New drug applications (NDA) | August 14, 2024 |
| Sunlenca | 61958-3002 | Kit | New drug applications (NDA) | December 22, 2022 |
| Sunlenca | 61958-3001 | Tablet, film coated | New drug applications (NDA) | December 22, 2022 |
| Descovy | 61958-2005 | Tablet | New drug applications (NDA) | January 7, 2022 |
| Biktarvy | 61958-2505 | Tablet | New drug applications (NDA) | October 7, 2021 |
| Epclusa | 61958-2205 | Pellet | New drug applications (NDA) | June 10, 2021 |
| Epclusa | 61958-2204 | Pellet | New drug applications (NDA) | June 10, 2021 |
| Veklury | 61958-2901 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | November 1, 2020 |
| Epclusa | 61958-2203 | Tablet, film coated | New drug applications (NDA) | March 19, 2020 |
| Harvoni | 61958-1805 | Pellet | New drug applications (NDA) | August 28, 2019 |
| Harvoni | 61958-1804 | Pellet | New drug applications (NDA) | August 28, 2019 |
| Harvoni | 61958-1803 | Tablet, film coated | New drug applications (NDA) | August 28, 2019 |
| Sovaldi | 61958-1505 | Pellet | New drug applications (NDA) | August 28, 2019 |
| Sovaldi | 61958-1504 | Pellet | New drug applications (NDA) | August 28, 2019 |
| Sovaldi | 61958-1503 | Tablet, film coated | New drug applications (NDA) | August 28, 2019 |
| Biktarvy | 61958-2501 | Tablet | New drug applications (NDA) | February 7, 2018 |
| Vosevi | 61958-2401 | Tablet, film coated | New drug applications (NDA) | July 18, 2017 |
| Vemlidy | 61958-2301 | Tablet | New drug applications (NDA) | November 10, 2016 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.